Neuropsychiatric disease in systemic lupus erythematosus can have diverse manifestations,
ranging from subtle cognitive dysfunction to overt life-threatening diseases such
as stroke and status epilepticus (
1
). The prevalence of neuropsychiatric manifestations varies widely, from 9% to 80%
in various series, depending on the definition, method of ascertainment, pattern of
referral, and patient ethnicity (
1
,
2
,
3
,
4
).To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Lupus and the central nervous system.Curr Opin Rheumatol. 1996; 8: 408-414
- Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus.J Rheumatol. 1999; 26: 432-439
- Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.Neurology. 2002; 58: 1214-1220
- Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.J Rheumatol. 2001; 28: 766-771
- Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.Arch Intern Med. 1996; 156: 1337-1344
- Risk factors for central nervous system involvement in systemic lupus erythematosus.QJM. 2000; 93: 169-174
- Therapy of lupus nephritis.N Engl J Med. 1986; 314: 614-619
- Controlled trial of pulse methylprednisolone versus two regimens of pulse CYC in severe lupus nephritis.Lancet. 1992; 340: 741-745
- Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial.Ann Intern Med. 1996; 125: 549-557
- Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.Ann Intern Med. 2001; 135: 248-257
- Treatment of diffuse proliferative lupus glomerulonephritis.Am J Kidney Dis. 2001; 38: 256-264
- Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.Arthritis Rheum. 2002; 46: 1003-1013
- Pulse cyclophosphamide for severe neuropsychiatric lupus.QJM. 1991; 81: 975Z-984
- Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus.Am J Med. 1995; 98: 32-41
- Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus.Clin Exp Rheumatol. 1996; 14: 295-299
- Acute transverse myelopathy in systemic lupus erythematosus.J Rheumatol. 1998; 25: 467-473
- Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus.Am J Med. 1999; 106: 65-69
- Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.N Engl J Med. 1988; 318: 1423-1431
- The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum. 1982; 25: 1271-1277
- Case definitions for neuropsychiatric syndromes in systemic lupus erythematosus.Arthritis Rheum. 1999; 42: 599-608
- Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington, DC1994
- Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.Lancet. 2000; 356: 701-707
Article info
Publication history
Accepted:
January 21,
2003
Received:
September 10,
2002
Identification
Copyright
© 2003 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
